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January 12, 2010:167–72emonstrated that plasma MCP-1 levels in 23 patients with
cute myocardial infarction (MI) increase as early as 3 h after
he onset of chest pain and reach their maximum at 24 h, with
urther gradual decline. We have no idea about the MCP-1
inetics, because we did not examine the measurement of
irculating MCP-1 in this study (1). Further studies will be
eeded on this important subject. In addition, in contrast to a
revious experimental study (4)—which shows that Ly-6Clo
CD14CD16 analogs) monocytes were found to be critical
or myocardial healing via myofibroblasts accumulation, angio-
enesis, and deposition of collagen—this study (1) did not show
ny significant effect of CD14CD16 monocytes on myocar-
ial salvage followed by reperfused MI. However, we could not
xclude the possibility that it might potentially be the result of
short period of observation (7 days after reperfusion).
We completely agree with Drs. Kavsak and and Jaffe’s suppo-
ition that data in a more diverse group, including those with
maller events diagnosed with cardiac troponin, would be impor-
ant to see whether difference exist between those groups. We also
gree with their idea that data about monocyte subgroups would
ossibly determine the optical timing of intervention in patients
ith MI without ST-segment elevation (5). Well-designed pro-
pective trials would highlight the effect of circulating distinct
onocyte subsets on the optimal timing of intervention in patients
or non–ST-segment elevation MI.
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eply
e thank Drs. Kavsak and Jaffe for their discussion regarding the
aper by Tsujioka et al. (1) and our accompanying editorial (2),nd we agree that the role of monocytes in the pathogenesis of
cute coronary syndromes (ACS) includes a lot of undiscovered
reas. Although the significance of high monocyte count for the
evelopment of atherothrombotic events and unfavorable course of
he recovery from them has been uniformly demonstrated, some
ontroversy still exists in relation to the precise mechanisms
esponsible for monocyte recruitment to the damaged myocardium
n general and monocyte chemoattractant protein (MCP)-1 in
articular (3,4).
In addition to a small study by Matsumori et al. (5), other
xperimental and clinical studies support significant up-regulation
f MCP-1 in ACS (as recently reviewed) (6). In the largest of such
tudies, the OPUS–TIMI (Orbofiban in Patients with Unstable
oronary Syndromes–Thrombolysis In Myocardial Infarction) 16
rial (5), MCP-1 was significantly increased in 2,270 patients with
CS compared with stable subjects and was an independent
rognostic factor for adverse outcomes (7).
Although the study by Kavsak et al. (8) on 216 patients with
CS did not reveal significant dynamics in MCP-1 at early stages
f ACS, this work was limited by only 2 time-points included in
he analysis (i.e., admission within 6 h after the onset of symptoms,
nd at 3 to 12 h later [median 6.5 h]), whereas monocytes are
nown to peak at 48 to 72 h after ACS onset. Additionally, the
tudy did not include a stable control group and thus might not
rovide the basis to challenge the hypothesis that “prompt up-
egulation of CCR-2 expressing CD14CD16- monocytes” (2).
In fact, a critical role of MCP-1 for mobilization of monocytes
rom bone marrow and their homing to the sites of damage has
een repeatedly shown. In contrast, mechanisms of recruitment of
D16 monocyte population are less established. These cells can
ifferentiate from CD16- monocytes or might be formed directly
n bone marrow (9). Indeed, their biological role in human cardiac
athology is only scarcely analyzed. The many observations re-
orted by Tsujioka et al. (1) (e.g., reduction of CD16 monocytes
n ACS patients at admission) do not have a robust explanation at
resent, thus raising further questions for future research. We
gree with Drs. Kavsak and Jaffe that “data in a more diverse
roup” of ACS patients on the dynamics of monocyte subsets are
eeded to shed further light on their clinical implications.
duard Shantsila, MD
Gregory Y. H. Lip, MD
Haemostasis Thrombosis and Vascular Biology Unit
niversity of Birmingham Centre for Cardiovascular Sciences
ity Hospital
irmingham B18 7QH
ngland, United Kingdom
-mail: g.y.h.lip@bham.ac.uk.
doi:10.1016/j.jacc.2009.08.044
EFERENCES
. Tsujioka H, Imanishi T, Ikejima H, et al. Impact of heterogeneity of
human peripheral blood monocyte subsets on myocardial salvage in
patients with primary acute myocardial infarction. J Am Coll Cardiol
2009;54:130–8.
. Shantsila E, Lip GYH. Monocyte diversity in myocardial infarction.
J Am Coll Cardiol 2009;54:139–42.
. Horne BD, Anderson JL, John JM, et al. Which white blood cell
subtypes predict increased cardiovascular risk? J Am Coll Cardiol
2005;45:1638–43.
45
6
7
8
9
I
C
o
W
B
A
l
n
c
r
c
t
a
t
v
L
s
o
f
C
a
t
c
p
d
t
c
p
(
p
c
s
(
i
c
p
(
C
C
m
s
f
c
e
i
t
*
W
*
D
W
B
M
W
E
R
1
171JACC Vol. 55, No. 2, 2010 Correspondence
January 12, 2010:167–72. Maekawa Y, Anzai T, Yoshikawa T, et al. Prognostic significance of
peripheral monocytosis after eperfused acute myocardial infarction: a
possible role for left ventricular remodeling. J Am Coll Cardiol
2002;39:241–6.
. Matsumori A, Furukawa Y, Hashimoto T, et al. Plasma levels of the
monocyte chemotactic and activating factor/monocyte chemoattractant
protein-1 are elevated in patients with acute myocardial infarction. J
Mol Cell Cardiol 1997;29:419–23.
. Shantsila E, Lip GY. Monocytes in acute coronary syndromes. Arte-
rioscler Thromb Vasc Biol 2009;29:1433–8.
. de Lemos JA, Morrow DA, Sabatine MS, et al. Association between
plasma levels of monocyte chemoattractant protein-1 and long-term
clinical outcomes in patients with acute coronary syndromes. Circula-
tion 2003;107:690–5.
. Kavsak PA, Ko DT, Newman AM, et al. Risk stratification for heart
failure and death in an acute coronary syndrome population using
inflammatory cytokines and N-terminal pro-brain natriuretic peptide.
Clin Chem 2007;53:2112–8.
. Serbina NV, Jia T, Hohl TM, Pamer EG. Monocyte-mediated defense
against microbial pathogens. Annu Rev Immunol 2008;26:421–52.
maging Surveillance for
ardiovascular Complications
f Cancer Therapy
e read with great interest the state-of-the-art paper by Yeh and
ickford (1) on the cardiovascular complications of cancer therapy.
lthough the review on monitoring for chemotherapy associated
eft ventricular (LV) dysfunction discussed the role of established
oninvasive tools, such as radionuclide ventriculography and echo-
ardiography, evidence on emerging tools such as cardiac magnetic
esonance (CMR) was not provided. The potential influence of
ancer therapy on the vascular system was also not addressed.
CMR, with its heightened spatial resolution compared with
hese established modalities, has become a valuable tool in the
ssessment of myocardial function, perfusion, and tissue charac-
erization (2). In addition, CMR has low intra- and interobserver
ariability and high test-retest reproducibility for measurement of
V function (3,4), characteristics that are crucial in clinical
ituations requiring accurate serial monitoring of LV function that
ccurs in cancer patients receiving potentially cardiotoxic therapy
or cancer. Also, CMR is considered by the American College of
ardiology Foundation and multiple professional societies as an
ppropriate tool for evaluation of LV function in patients with
echnically suboptimal echocardiograms and evaluation of specific
ardiotoxic therapy associated with cardiomyopathy (5).
Tissue characterization by CMR is a robust technique of
rognostic importance (6). In a pilot study, Wassmuth et al. (7)
emonstrated the strength of CMR to detect subclinical cardio-
oxic effects of anthracyclines. Increase of relative myocardial
ontrast enhancement of 5 on day 3 compared with baseline
redicted a significant decline in LV ejection fraction at 28 days
p  0.05).
An emerging concern for cancer survivors is the increasing
revalence of cardiovascular events (8). For survivors of breast
ancer and hematologic malignancies, cardiovascular events are the
econd most common cause of mortality after cancer recurrence
8). At present, there are few studies that have been performed to
dentify subclinical markers of increased cardiovascular events in
ancer survivors. Increased aortic stiffness is an independentredictor of cardiovascular events beyond the Framingham score
9,10). In a soon-to-be published prospective case-control study,
haosuwannakit et al. (11), observed a significant increase in
MR measures of aortic stiffness among cancer patients within 4
onths of exposure to anthracycline chemotherapy. As cancer
urvivors experience higher incidence of cardiovascular events,
urther studies will be necessary to identify subclinical markers of
ardiovascular disease.
CMR holds great potential in the comprehensive cardiovascular
valuation of cancer patients on therapy and should therefore be
ncluded in discussions on contemporary cardiovascular imaging of
his growing patient population.
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